Optinose Announces Preliminary Third Quarter 2020 XHANCE Net Revenue of $15.4 Million
October 22, 2020 07:00 ET
|
Optinose, Inc.
Preliminary XHANCE Net Revenue Growth of 78% Compared to Third Quarter 2019 and 50% Compared to Second Quarter 2020 Conference Call and Webcast to be held November 5, 2020 at 8:00 a.m. Eastern...
Optinose to Present at the Cantor Virtual Global Healthcare Conference
September 14, 2020 08:00 ET
|
Optinose, Inc.
YARDLEY, Pa., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Announces Pricing of Public Offering of Common Stock
August 14, 2020 08:04 ET
|
Optinose, Inc.
YARDLEY, Pa., Aug. 14, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, today announced the...
Optinose Announces Proposed Public Offering of Common Stock
August 13, 2020 16:26 ET
|
Optinose, Inc.
YARDLEY, Pa., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, today announced the...
Optinose Reports Second Quarter 2020 Financial Results and Recent Operational Highlights
August 04, 2020 07:00 ET
|
Optinose, Inc.
Company reports second quarter 2020 XHANCE net revenue of $10.3 million Second quarter 2020 XHANCE prescriptions increased 84% from second quarter 2019 Conference call and webcast to be held today...
Optinose Announces Reporting Date for Second Quarter 2020 Financial Results
July 30, 2020 16:01 ET
|
Optinose, Inc.
YARDLEY, Pa., July 30, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose names Catherine E. Owen as Director
July 29, 2020 16:01 ET
|
Optinose, Inc.
YARDLEY, Pa., July 29, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Announces XHANCE Co-Promotion Agreement with Kaléo
July 08, 2020 16:15 ET
|
Optinose, Inc.
YARDLEY, Pa., July 08, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Announces Anti-COVID-19 Product Candidate
June 30, 2020 08:00 ET
|
Optinose, Inc.
YARDLEY, Pa., June 30, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose to Present at the BMO 2020 Prescriptions for Success Healthcare Conference
June 22, 2020 08:30 ET
|
Optinose, Inc.
YARDLEY, Pa., June 22, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...